Jonathan P. Graham - May 2, 2022 Form 4 Insider Report for AMGEN INC (AMGN)

Role
EVP, Gen. Counsel & Secy.
Signature
/s/ Jonathan P. Graham
Stock symbol
AMGN
Transactions as of
May 2, 2022
Transactions value $
-$130,701
Form type
4
Date filed
5/4/2022, 07:51 PM
Previous filing
Apr 29, 2022
Next filing
May 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMGN Common Stock Award $0 +3.38K +6.95% $0.00 52K May 2, 2022 Direct F1
transaction AMGN Common Stock Tax liability -$131K -566 -1.09% $230.92 51.4K May 3, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMGN Nqso (Right to Buy) Award $0 +27.6K $0.00 27.6K May 2, 2022 Common Stock 27.6K $230.92 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.
F2 These shares include the following RSUs granted under the Company's equity plans: 1,074 RSUs which will vest in one installment of 1,074 on 5/3/2023; 6,148 RSUs which vest in one installment of 3,028 on 11/1/2022 and one installment of 3,120 on 11/1/2023; 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024; 3,797 RSUs which vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025; and 3,377 RSUs which vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and 1,149 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F3 These shares include 902 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F4 These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.